Brief: Abivax Sa Says Cash And Cash Equivalents Of Eur 180.5 Million As Of September 30, 2024
Brief: Abivax Announces First Patient Enrolled In Enhance-Cd, The Phase 2B Trial Of Obefazimod In Crohn’S Disease
Brief: Abivax Reports Positive Interim Efficacy And Safety Analysis Of Obefazimod
Brief: Abivax Provides Update on Ulcerative Colitis Combination Therapy Program Strategy
Brief: Abivax Expects To Be Able To Finance Its Operating Cash Flow Requirements Into Q4 2025
Abivax SA expected to post a loss of 74 cents a share - Earnings Preview
Brief: Abivax Announces Abtect Phase 3 Trial Achieves Key Enrollment Milestone
Brief: Abivax Provides Operational And Key Program Update
Brief: Abivax Sees Sufficient Funds To Finance Operations Into Q4 2025
Abivax SA expected to post a loss of 60 cents a share - Earnings Preview
Brief: Abivax Provides 2024 Strategic Outlook, Lays Out Key Milestones Over Next 12 Months
Brief: Abivax: Closing of IPO on Nasdaq Global Market
U.S. STOCKS ON THE MOVE-Paypal, Bowlero, Dycom
France's Abivax plunges after low-end US IPO pricing
Brief: Abivax Announces Trading Resumption On Euronext Paris
Brief: Abivax Announces Pricing For Nasdaq IPO
Brief: Abivax Temporarily Halts Trading On Euronext Paris
Brief: Abivax says IPO offering price between $11.60 and $13.00 per ADS
Brief: Abivax SA Offering An Aggregate Of 18.7 Million Ordinary Shares In A Global Offering - SEC Filing